The sequencing firm is offering 19.4 million shares of common stock at $4.47 per share and plans to use the proceeds for product launches, among other uses.
The sequencing firm said the COVID-19 pandemic had a negative impact on revenues, which totaled $17.1 million, down from $24.6 million in the prior-year period.
In Science this week: Fiber-seq method to examine regulatory architecture, mutations in SOST associated with osteoporosis drug-linked cardiovascular events, and more.
Taiwan-based Personal Genomics, which is developing a new single-molecule sequencing platform, has previously sued PacBio for patent infringement in the US.
The methods exploit a feature of Oxford Nanopore's technology that ejects molecules mid-read, enabling a new level of control over human DNA sequencing runs.
All three methods build on the use of methyltransferases to mark accessible regions of the genome, using nanopore sequencing to detect the modifications.
